Shen Lian Biomedical: The Phase II clinical study of the innovative drug UB-221 injection has completed the enrollment of all subjects

On August 31, Shen Lian Biomedical announced that the company recently received a "Notice" from its investee company, Shizhiyuan, regarding the progress of the Phase II clinical study of the innovative drug UB-221 injection. As of the date of this announcement, the project has completed the enrollment of all 145 subjects. Shizhiyuan holds the marketing authorization and all commercialization rights for UB-221 in mainland China, including research and development, production, and sales. UB-221 is a proprietary drug developed by the company's second largest shareholder, United Biomedical, Inc. This project is a next-generation product developed by Dr. Zhang Ziwen, the inventor of the anti-IgE therapy, and is a humanized original monoclonal antibody in a subcutaneous injection form